Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) will likely be releasing its earnings data before the market opens on Friday, February 7th. Analysts expect the company to announce earnings of $11.21 per share and revenue of $3.76 billion for the quarter. Investors interested in participating in the company's conference call can do so using this link.
Regeneron Pharmaceuticals Stock Performance
Regeneron Pharmaceuticals stock opened at $683.08 on Friday. Regeneron Pharmaceuticals has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $75.06 billion, a PE ratio of 16.90, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The firm's 50 day simple moving average is $723.36 and its 200 day simple moving average is $928.61.
Analysts Set New Price Targets
REGN has been the topic of several research analyst reports. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday. StockNews.com lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,004.57.
Read Our Latest Stock Report on REGN
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
